dactinomycin has been researched along with plitidepsin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borsotti, P; Broggini, M; D'Incalci, M; Erba, E; Faircloth, GT; Galliera, E; Giavazzi, R; Jimeno, J; Marchini, SV; Sironi, M; Taraboletti, G | 1 |
1 other study(ies) available for dactinomycin and plitidepsin
| Article | Year |
|---|---|
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Topics: Antineoplastic Agents; Apoptosis; Autocrine Communication; Cell Division; Dactinomycin; Depsipeptides; DNA Primers; Electrophoretic Mobility Shift Assay; Endothelial Growth Factors; Half-Life; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, T-Cell; Luciferases; Lymphokines; Peptides, Cyclic; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Synthesis Inhibitors; RNA, Messenger; Signal Transduction; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors | 2003 |